A summary of published research, not medical advice. See the Disclaimer.
This section covers prescription drugs that people discuss for off-label or longevity use, such as metformin, rapamycin, modafinil and acarbose.
These are prescription-only. Off-label use means using a drug for something it isn't approved for, and the evidence for that use is often much weaker than for the approved one. Nothing here replaces a clinician who knows your history, other medications and test results.
Category rules
- No sourcing. Nothing on getting these drugs without a prescription, from overseas pharmacies or from online prescribers.
- No dosing guidance. Doses appear only as the amounts a cited study used.
- Every article opens with a Regulatory status section listing what the drug is approved for, where, and its prescription status, with sources and the date checked.
- Approved uses and off-label claims are kept in separate sections.
- Known serious risks and interactions from the drug's label are always included.
¶ Articles (3)
- Metformin Helps (strong evidence)
Research summary of human studies on metformin, a prescription drug sold as Glucophage and used in type 2 diabetes.
- Rapamycin (sirolimus) No supported effect
Research summary of human studies on rapamycin, also known as sirolimus or Rapamune, an mTOR-blocking immunosuppressant, and related rapalogs such as everolimus.
- Semaglutide Helps a lot (strong evidence)
Research summary of human studies on semaglutide, a GLP-1 receptor agonist sold as Ozempic and Wegovy injections and as Rybelsus tablets.
Each article has a Studies page listing the indexed trials and reviews, scored for design. All of them are in the study browser.